We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Creo Medical Group Plc | LSE:CREO | London | Ordinary Share | GB00BZ1BLL44 | ORD GBP0.001 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 14.25 | 0.00 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 14.00 | 14.50 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Surgical,med Instr,apparatus | 30.8M | -21.7M | -0.0600 | -2.38 | 51.51M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 14.25 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 31/10/2024 | 16:36 | UK RNS | Creo Medical Group PLC Total Voting Rights |
| 24/10/2024 | 14:27 | UK RNS | Creo Medical Group PLC Director/PDMR Shareholding (Replacement) |
| 24/10/2024 | 13:33 | UK RNS | Creo Medical Group PLC Director/PDMR Shareholding |
| 21/10/2024 | 09:06 | UK RNS | Creo Medical Group PLC Director/PDMR Share Dealings |
| 18/10/2024 | 09:26 | UK RNS | Creo Medical Group PLC Result of General Meeting & TVR |
| 17/10/2024 | 16:29 | UK RNS | Creo Medical Group PLC Result of Retail Offer |
| 04/10/2024 | 06:00 | UK RNS | Creo Medical Group PLC Extension of Retail Offer Closing Date |
| 01/10/2024 | 12:34 | ALNC |  EARNINGS: Savannah Energy swings to profit; Creo loss widens |
| 01/10/2024 | 06:00 | UK RNS | Creo Medical Group PLC Result of Placing |
| 30/9/2024 | 14:50 | UK RNS | Creo Medical Group PLC Retail Offer for up to £5.0 million |
Creo Medical (CREO) Share Charts1 Year Creo Medical Chart |
|
1 Month Creo Medical Chart |
Intraday Creo Medical Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 10/12/2024 | 20:08 | Creo Medical Group PLC 2023 | 973 |
| 08/6/2023 | 15:55 | Creo Medical Group... 2017 | 623 |
| 03/12/2018 | 12:41 | First use of Speedboat in mainland Europe | - |
| 09/12/2016 | 14:52 | China Real Estate Opportunities | 3 |
| 27/6/2012 | 11:52 | having a look...... | 1,095 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-12-10 16:39:48 | 14.25 | 50,000 | 7,125.00 | O |
| 2024-12-10 16:25:38 | 14.50 | 20 | 2.90 | O |
| 2024-12-10 16:25:37 | 14.50 | 7 | 1.02 | O |
| 2024-12-10 16:25:33 | 14.25 | 10,000 | 1,425.00 | O |
| 2024-12-10 16:24:24 | 14.35 | 5,200 | 746.20 | O |
| Top Posts |
|---|
Posted at 10/12/2024 08:20 by Creo Medical Daily Update Creo Medical Group Plc is listed in the Surgical,med Instr,apparatus sector of the London Stock Exchange with ticker CREO. The last closing price for Creo Medical was 14.25p.Creo Medical currently has 361,476,442 shares in issue. The market capitalisation of Creo Medical is £51,510,393. Creo Medical has a price to earnings ratio (PE ratio) of -2.38. This morning CREO shares opened at - |
Posted at 12/11/2024 18:28 by parob "The recent announcement of an agreement for the sale of 51% of Creo Medical Europe represents an excellent strategic partnership opportunity for Creo. The partnership will support our continued commercial growth through Creo Europe with access to the wider Micro-Tech product portfolio secured under the Creo Brand. This product range will also be available to Creo's core sales teams globally to complement our advanced energy portfolio. Additionally, we have the potential to secure product registration and co-branding in China with our advanced energy products which will help our APAC growth in the future. "Over the next six to 12 months, we expect to see the continued growth rate of our core sales, driven by Speedboat UltraSlim, but with developing progress in our other product groups. I thank shareholders for their continued support during the period and look forward to providing further updates." |
Posted at 12/11/2024 18:25 by purchaseatthetop It means hopes were raised turn of year 2023 with the release of Speedboat and the promise of immediate sales. But then share price drifted as sales did not materialise. You see that it is really difficult to actually sell in the USA as shown by AGL, POLX and also STX. Medical devices are the worst. It takes years. STX has been through this hell snd is now growing exponentially. $11.5m revenue in Q4 24 with $20m in H2 24. Only $11m in H1 24. CREO is right at the start of this curve.“Knowing the potential that having a device that is compatible with all major endoscopes brings, we are energised to get the device into the hands of clinicans to allow them to treat their patients, for more indications and improve lives. With significant demand for this product already indicated from existing and potential Speedboat users, we will continue our early market release ahead of the full market launch in early 2024.” |
Posted at 12/11/2024 16:05 by purchaseatthetop Actually I was benchmarking STX and CREO…“Interesting comparisons between STX and CREO. So thanks to Parob for coming to the board to try to upset me. CREO have spent £157m if retained losses getting to losing £10m every six months. Overhead of £40m a year. Sales about £30m. No revenue growth. 47% gross margin. STX have spent about the same of retained losses getting to losing the same amount every six months. Overhead about the same. 250% revenue growth with similar revenue now. same gross margin. Likely £65m plus revenue 2025. STX market cap £21k CREO market cap £75m Certainly seems one is under or overvalued. Very similar in many ways.” Seems like valid analysis. Just checking my investment in STX makes sense. I would not have noticed CREO ever except for Parob coming over to taunt me. But he did. And so I got interested. Happy to be involved in discussions. Good to meet you all. |
Posted at 12/11/2024 12:14 by purchaseatthetop The problem is that it is going nowhereTotal revenue of £15.2m (H1-2023: £15.7m) Gross margin stuck at 47% Losses of £10m each six months. The hope of the 51% strategic sale looks very uncertain We announced on 18 September 2024 that Creo has entered into a binding agreement with Micro-Tech (NL) International B.V., a wholly owned subsidiary of Micro-Tech (Nanjing) ("Micro-Tech") for the sale of 51% of the issued share capital of Creo Medical S.L.U. ("Creo Medical Europe"), a wholly owned subsidiary of Creo, at an equity value of €72m (the "Sale") on a cash-free, debt-free basis. The net proceeds payable to Creo from the Sale (the "Proceeds") will strengthen the Group's balance sheet, enabling us to continue to invest in our core Creo and Kamaptive business and deliver on our commercial and operational objectives. The Proceeds are expected to be approximately €30m, which will be payable in cash on completion. Ongoing shareholder terms have also been agreed which include a future exit framework for Creo. Along with other customary conditions, completion of the Sale is contingent on Micro-Tech obtaining Outbound Direct Investment clearance in China along with Foreign Direct Investment clearances in Spain, France, Belgium and Germany. Whilst there is no certainty as to receipt or timing of receipt of the necessary approvals to enable completion, it is expected that completion will take place during Q1 2025 dependent on these relevant clearances being obtained. Too many future uncertains. |
Posted at 12/11/2024 10:01 by parob Few more for me on that drop. The share price down here is very close to the all time low which we hit on Friday of last week at around 16.25p so there really are not that many in profit around this level. There may be a few that sell for 10/15% I suppose and perhaps thats what we saw earlier. I am hopeful the recovery will speed up once these initial profit takers are out. At 18p to buy the share price is 25% cheaper than the recent £12M placing price of 24p where the directors put about £750k in. |
Posted at 11/11/2024 08:38 by parob Good to see strong interest this morning following Friday’s high volume day where we saw a lovely dragonfly doji candle form on the chart, hopefully signalling the bottom.The last time CREO did a placing (Feb 2023), the placing price was 20p and I think the lowest price the share price dropped to was 24/25p so demand was there. I think a large seller has provided a lovely entry opportunity here. It was 30% lower than the placing price (24p) at one point and even at 20p you’re still getting an almost 20% discount. Considering the price action on Friday I think that late 724K delayed sell I noticed from Thursday was the final amount from the seller. Added more today. |
Posted at 06/11/2024 09:47 by 1swifty Frustrating times with Creo. No news, share price dropping, lots of sells. Crazy fall since the impressive and positive news of stake sold in Creo Europe. If sale goes through cash available could be significant percentage of current market capital thus making current share price crazy low. |
Posted at 19/10/2024 09:41 by networker I am not aware if CREO made any comments at yesterday's EGM held in Bristol.Here are their recent (official) comments on recent events:- "As you know the Company announced its strategic partnership with Micro-Tech and the intended disposal of a 51% stake in Creo Europe. Unfortunately, Creo Medical wasn’t in a position to arrange the Placing to coincide with the disposal. After the Micro-Tech news was released a broker’s research note was published that restated again the analyst’s view that the Company had a funding requirement, and that they continued to assume that Creo Medical would need additional cash to bridge through to proceeds from the disposal (although less than previously expected given the transaction). Given the current environment of the equity markets this led to a drag on the share price. In addition, since the announcement of the fundraising, there has been an institutional seller in the market (for non-Creo specific reasons), which has caused further downward pressure. At the same time as there has been a lack of buying activity across equity markets generally due to concerns about what might be announced in the upcoming budget. The Company and its advisers are working hard to ensure that this overhang is cleared and that the share price recovers. " |
Posted at 17/10/2024 16:36 by bloomberg2 17 October 2024Creo Medical Group plc("Creo" or the "Company") Result of Retail Offer Further to the announcements dated 30 September 2024 and 4 October 2024 in relation to the Retail Offer, Creo announces that, following the closing of the Retail Offer by BookBuild earlier today, 369,109 Retail Offer Shares will be issued at an Issue Price of 24 pence per Retail Offer Share in connection with the Retail Offer. Consequently, a total of 50,369,109 New Ordinary Shares, comprising 50,000,000 Placing Shares and 369,109 Retail Offer Shares will be issued conditional on the passing of the Resolutions by Shareholders at the General Meeting to be held on 18 October 2024. Admission, settlement and dealings Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to take place at 8:00 a.m. on 21 October 2024 and dealings in the New Ordinary Shares are expected to commence at 8.00 a.m. on 21 October 2024 or such later time and/or date as the Joint Bookrunners and the Company agree (being in any event no later than 8.00 a.m. on 11 November 2024). The New Ordinary Shares, when issued, will be credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of issue. Capitalised terms used but not defined in this announcement have the same meanings as set out in the circular to Shareholders dated 1 October 2024. For further information please contact: Creo Medic |
Posted at 18/9/2024 20:17 by dr biotech Yeah, whilst buying shares is always a risk, the major risk here has passed. Now they just have to prove they can sell their core products.I'm not on twitter, but some chinese guy has posted this (in chinese). Doesn't add a lot but its written from their point of view Nanwei Medical: Announcement on the purchase of 51% equity of Creo Medical S.L.U. [Sun] Basic situation: It is planned to use its own funds to purchase 51% equity of the target company CME through Nanwei Holland. The estimated transaction amount of this transaction is not more than 36.72 million euros (equivalent to approximately RMB 289.4821 million). After the completion of this transaction, the company will hold 51% equity of CME through Nanwei Holland. [Sun] Target company: A wholly-owned subsidiary of Creo, it is a channel company for the sales of medical device products. Its distribution products include Creo's self-developed products and medical device products in the fields of digestion, urology, respiratory, disposable endoscopes, etc. produced by other related medical device companies. Among them, endoscopic consumables and disposable endoscopes account for nearly 70% of the target company's revenue in 2023. The main business is concentrated in Western Europe, covering the United Kingdom, Spain, France, Germany, Belgium, Luxembourg and other countries. The revenue in 2023/2024H1 is 31.942 million/16.593 million euros, and the net profit is 3.468 million/1.574 million euros respectively. [Sun] Acquisition price: Combining the income method and the market value of the original shareholder Creo, the equity value of the target company is finally determined to be 72 million euros after friendly negotiation between the two parties. Valuation calculation: Referring to the content of the announcement, the PE of the target company in 2023 corresponding to this acquisition is about 21 times, and the PS is about 2.25 times. [Sun] Transaction funds: The funds for this transaction come from the company's own funds. As of June 30, 2024, the company's asset-liability ratio is 14.81%, and the company's monetary funds are 122,329.27 million yuan. The transaction amount accounts for about 23.66% of the company's monetary funds. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
